Ignite Creation Date:
2025-12-24 @ 4:49 PM
Ignite Modification Date:
2025-12-29 @ 10:43 PM
Study NCT ID:
NCT04195750
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-29
First Post:
2019-12-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-02-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-09-17
Completion Date Type:
ESTIMATED
First Submit Date:
2019-12-10
First Submit QC Date:
None
Study First Post Date:
2019-12-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-09
Results First Submit QC Date:
None
Results First Post Date:
2025-04-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-09
Last Update Post Date:
2025-04-29
Last Update Post Date Type:
ACTUAL